NFKB1 and monocytic leukemia: Our findings are in accord with the suppression of an NF-κB pathway by iguratimod in a human monocytic leukaemia cell line (THP-1)26,27 and cultured human synovial cells47,48, and in line with the identification of iguratimod as an inhibitor of macrophage migration inhibitory factor39.